Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 8—August 2023
Research

Multidrug-Resistant Bacterial Colonization and Infections in Large Retrospective Cohort of Mechanically Ventilated COVID-19 Patients1

Davide Mangioni, Liliane Chatenoud, Jacopo Colombo, Emanuele Palomba, Fernando A. Guerrero, Matteo Bolis, Nicola Bottino, Giuseppe Breda, Maria V. Chiaruttini, Gabriele Fior, Manuela Marotta, Giovanni Massobrio, Caterina Matinato, Antonio Muscatello, Paola Previtali, Sara Santambrogio, Francesca Tardini, Gianluca Zuglian, Giacomo Grasselli, Roberto Fumagalli, Andrea Gori, Nino Stocchetti, Gianpaola Monti2, Alessandra Bandera2, and the MDR in FIERA Study Group3
Author affiliations: Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy (D. Mangioni, E. Palomba, M. Bolis, N. Bottino, G. Breda, G. Massobrio, C. Matinato, A. Muscatello, G. Zuglian, G. Grasselli, A. Gori, N. Stocchetti, A. Bandera); University of Milan, Milan (D. Mangioni, E. Palomba, G. Grasselli, A. Gori, N. Stocchetti, A, Bandera); Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan (L. Chatenoud, M.V. Chiaruttini); Harvard Medical School, Boston, Massachusetts, USA (J. Colombo); ASST Grande Ospedale Metropolitano Niguarda, Milan (J. Colombo, F.A. Guerrero, G. Fior, M. Marotta, P. Previtali, S. Santambrogio, F. Tardini, R. Fumagalli, G. Monti); ULSS 3 Serenissima, Venice, Italy (G. Zuglian); University of Milano-Bicocca, Milan (R. Fumagalli)

Main Article

Table 2

Incidence rate of MDRO events, overall and divided by infection site, of patients admitted to ICU in Milan, Italy, October 2020–May 2021, who had no MDRO isolates within the first 48 h of admission*

Characteristic Infections
VALRTIs BSIs UTIs Total
MDRO events, first colonization plus new infections
 NA
 NA
 NA
 41.68 (36.98–46.99)
First MDRO colonization
 NA
 NA
 NA
 29.97 (26.34–34.1)
New MDRO infection
 9.44 (7.58–11.74)
 4.89 (3.55–6.75)
 0.47 (0.14–1.08)
 14.99 (12.36–18.19)
New non-MDRO infection
 33.25 (29.04–38.07)
 11.62 (9.23–14.64)
 4.19 (2.97–5.72)
 50.12 (44.59–56.32)
Overall new infections, MDRO plus non-MDRO 42.41 (37.81–47.58) 16.57 (13.51–20.31) 5.15 (3.36–6.26) 65.13 (58.76–72.2)

*Values are IR/1,000 person-days (95% CIs). The time considered for IRs was set from ICU admission to discharge, except for VALRTI, where total intubation time was considered. BSIs, bloodstream infections; ICU, intensive care unit; IR, incidence rate; MDRO, multidrug-resistant organism; NA, not applicable (MDRO colonization refers to patients and not infection sites); UTIs, urinary tract infections; VALRTIs, ventilator-associated lower respiratory tract infections.

Main Article

1Preliminary results were presented at the European Congress of Clinical Microbiology and Infectious Diseases, 2022, Lisbon, Portugal, April 23‒26, 2022 (abstract no. 02641).

2These senior authors contributed equally to this article.

3Study group members are listed at the end of this article.

Page created: June 22, 2023
Page updated: July 20, 2023
Page reviewed: July 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external